Advice

following a re-submission

agomelatine (Valdoxan®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of major depressive episodes in adults.

When used in a flexible dosing schedule, agomelatine significantly reduced the symptoms of depression and increased the number of patients who responded to treatment compared with
placebo. There are no comparative data from clinical studies with existing second line antidepressants using depression as the primary outcome.

The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

The licence holder has indicated their intention to resubmit.

Download detailed advice135KB (PDF)

Download

Medicine details

Medicine name:
agomelatine (Valdoxan) Resubmission
SMC ID:
564/09
Indication:
Major depressive epsiodes in adults.
Pharmaceutical company
Servier Laboratories Ltd
BNF chapter
Central nervous system
Submission type
Resubmission
Status
Not recommended
Date advice published:
13 September 2010